Yesterday’s News — January 5, 2015

because nobody’s ready for today yet



While it’s the first day back from vacation for some of us, others have been working through the holidays. Like Michigan Governor Rick Synder who, on the day after Christmas, signed off on a bill requiring welfare recipients “suspected” of drug use to undergo screenings or forfeit their benefits — despite plenty of evidence that drug use is no more prevalent among the poor than other social classes as well as financial analysis that suggests the program won’t actually save the state much money. Follow the link below to The Washington Times and Kellan Howell’s more in-depth coverage:



Al-Jeezera has an article about the effects of Marinol on burn victims who, according to Gordon Lindberg, director of the University of Colorado Burn Unit, were suffering from marijuana withdraw. In what might be the least scientific survey ever conducted of cannabis tolerance in people who exploded themselves, the article also suggests, at the very bottom, that Marinol may be a better alternative for burn pain than heavy narcotics. Read the article by Serene Fang and Lori Jane Gilha here:



The Justice Department continues to confuse everyone with their classification of cannabis as a Schedule 1 narcotic. Less than one month after President Obama signed legislation that would prohibit the federal government from interfering with state medical marijuana practices, Assistant U.S. Attorney Gregory Broderick wrote, in reference to a Sacramento court case that challenges the Schedule 1 status of cannabis, that enough evidence exists to support the administration’s continued claim that “this psychoactive, addictive drug is not accepted as safe for medical use at this time, even with medical supervision.” Bob Egelko at the SF Gate has some more details about the Sacramento court proceedings:



But if conspiracy theories are your thing, High Times is suggesting that the government has no intention of reclassifying cannabis for the masses but will allow certain drugs through on a case by case basis, just as it did with Marinol. Much to the benefit, of course, of big pharma. Mike Adams, who (for purposes of full disclosure) calls himself a “smut enthusiast,” claims that GW Pharmaceuticals has been conducting clinical trails in the United States for the past year with the intention of introducing its own, federally approved, cannabis derivatives: 


Posted in The Informant and tagged , , , , , , , , , .

Leave a Reply

Your email address will not be published. Required fields are marked *